Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes | Zendy

Gian Paolo Fadini | Zendy; Benedetta Maria Bonora | Zendy; Roberta Cappellari | Zendy; Lisa Menegazzo | Zendy; Monica Vedovato | Zendy; Elisabetta Iori | Zendy; Maria Cristina Marescotti | Zendy; Mattia Albiero | Zendy; Angelo Avogaro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes

Author(s) -

Gian Paolo Fadini,

Benedetta Maria Bonora,

Roberta Cappellari,

Lisa Menegazzo,

Monica Vedovato,

Elisabetta Iori,

Maria Cristina Marescotti,

Mattia Albiero,

Angelo Avogaro

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-3716

Subject(s) - linagliptin , medicine , progenitor cell , monocyte , cd14 , type 2 diabetes , endocrinology , cd34 , diabetes mellitus , immunology , pharmacology , receptor , stem cell , biology , microbiology and biotechnology

Circulating cells, including endothelial progenitor cells (EPCs) and monocyte subtypes, are involved in diabetic complications. Modulation of these cells may mediate additional benefits of glucose-lowering medications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research